



Food For Thought


Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in treating central nervous system (CNS) disorders. Focusing on serious and difficult-to-diagnose neurodegenerative diseases, Accera develops innovative therapeutic options to improve quality of life for patients and their families. The company is pioneering unique scientific approaches to CNS disorders, through products with novel mechanisms-of-action that target the underlying causes, not just the symptoms themselves.

As an industry innovator, Accera is developing therapies that address metabolic deficiencies associated with certain neurodegenerative diseases and provide an alternative energy source for brain cells. Accera has developed a patent estate that provides broad coverage and protection for use of medium chain triglycerides in neurodegenerative disease.


Role of Metabolism

Metabolism is the process that makes energy available to the body. The human brain is one of the most metabolically active organs in the body, and under normal circumstances, it relies almost exclusively on glucose as its source of energy. The real work of the brain goes on in the cells — about 100 billion nerve cells (neurons) that connect at more than 100 trillion points with branches.

Memories, thoughts and feelings are created by the signals that travel through this amazing network. The normal, healthy brain depends on circulating glucose for most of its functions. In Alzheimer's disease (AD), glucose is poorly utilized by nerve cells and brain function is decreased. Numerous scientific and clinical studies have shown that a dramatic drop in glucose use in certain areas of the brain may start 10 to 20 years before any symptoms of AD appear.



Normal Brain




AD Brain

Deprived of glucose, their primary source of energy, these brain cells don't function well. By introducing an alternative source of energy to nerve cells, it may be possible to improve brain activity and cognitive function, thus lessening the devastating effects of Alzheimer's disease and helping to manage the disease.

Axona™

Accera's lead product, Axona, is a new first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD. Alzheimer's disease is characterized by substantial decreases in the brain's ability to metabolize glucose. Axona is metabolized by the body into ketones, which can be used by the brain as an alternative energy source. In randomized, placebo-controlled clinical trials, Axona has been shown to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD. Axona is marketed as an adjunctive therapy to AD drugs and is dispensed by prescription through pharmacies.





Ketone bodies provide an alternative energy source to energy deprived brain cells. In this figure, ketone bodies enter the neuron and are metabolized by mitochondria to provide ATP, the universal energy currency of the body.

Alzheimer's Disease

In the U.S., 5.2 million people are living with AD which is now the 6th leading cause of death. The disease attacks the brain's nerve cells, resulting in loss of memory, thinking and language skills, and behavioral changes. The cause of Alzheimer's disease is unknown, and there is currently no cure for AD, but pharmaceutical, behavioral and dietary treatments may help with both cognitive and behavioral symptoms.

The direct and indirect costs of AD and other dementias amount to more than \$148 billion each year. Neither Medicare nor most private health insurance covers the long-term care. Alzheimer's disease is costing U.S. business \$61 billion/year, including \$36.5 billion in caregiving, particularly lost productivity from caregiver absenteeism.*

Age Associated Memory Impairment (AAMI)

Age Associated Memory Impairment is a common condition characterized by very mild symptoms of cognitive decline that occur as part of the normal aging process and are the result of physiological changes in the aging brain and not a specific neurological disorder.

The decline of cognitive function with age can be a huge burden on individuals, families, caregivers and society as a whole. According to a preliminary study based on data from the Health & Retirement Study, 10 percent of people age 70 and older have moderate to severe cognitive impairment and prevalence rises sharply with age. Also, data indicate that the total national cost of caregiving in the home for older adults with cognitive impairment has been estimated at \$18 billion.

Management


Accera is backed by experienced management and commercialization teams, representing 100+ combined years of experience with a deep understanding of the pharmaceutical and biotech industries. The management team has been involved in the successful commercialization of a number of start-up companies and numerous drugs in the CNS category.

*Alzheimer's Association. (2008). 2008 Alzheimer's Disease Facts and Figures. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 4 (2): 110-133. doi: 10.1016/j.jalz.2008.02.005


Products & Pipeline

The company's product pipeline includes new approaches to Alzheimer's disease (AD), Parkinson's disease and other age-related memory loss disorders. These products are in advanced clinical development, where they have demonstrated significant efficacy and outstanding safety.

Product Pipeline *Medical Foods Development*



Drug Development



Axona™

Axona™ is a medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD.

AC-0523

AC-0523 addresses mitochondrial dysfunction in Huntington's disease. The compound is in early preclinical testing and manufacturing process development.

AC-8632

AC-8632 is a non-selective inhibitor of both isoforms of acetyl-coenzyme A carboxylase that plays a key role in fatty acid synthesis. It is being studied for the treatment for Parkinson's disease.



Accera, Inc. | 380 Interlocken Crescent Suite 780
Broomfield, Colorado 80021 | Tel 303.999.3700 | Fax 303.999.3799
www.acerapharma.com

Copyright 2009 Accera, Inc. Axona is a Trademark of Accera, Inc.

AC-08-003